GlobalData on MSN21h
Novo Nordisk plans new study for CagriSema, targets 2026 submission
CagriSema, considered a successor to Wegovy, is Novo Nordisk’s most likely route of gaining GLP-1RA market share back from ...
Denmark Could Ban Or Push Ozempic, Wegovy And Shipping Prices Through The Roof If Trump Escalates Over Greenland
Donald Trump's renewed push to take control of Greenland is setting off a high-stakes showdown with Denmark, a small country ...
Investor's Business Daily on MSN40m
IBD 50 Stock Hims & Hers Faces Backlash Over Provocative Super Bowl Ad
Hims stock surged above a profit-taking zone Friday after facing backlash over its provocative Super Bowl ad that criticized the makers of approved weight-loss drugs. Please watch the video at ...
Parade on MSN3h
Ozempic Could Get Way Too Expensive Under Trump—Here's What You Can Do
President Trump’s proposed tariffs on Denmark could have costly consequences for Americans relying on GLP-1 medications like ...
Super Bowl Ad Raises Questions About Compounded Versus Branded Obesity Meds
An ad airing Super Bowl Sunday features “America’s deadliest epidemic,” obesity, and what can be done about it with the use ...